STOCK TITAN

LifeVantage (LFVN) insider report: PRSUs convert; Kristen Cunningham sells 21,801 shares

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Kristen Cunningham, Chief Sales Officer of LifeVantage Corp (LFVN), reported changes in her beneficial ownership on a Form 4 covering transactions dated 08/31/2025. The filing shows conversion/acquisition of 17,752 and 26,150 performance restricted stock units (PRSUs) into common stock at no cash price, an ESPP purchase of 254 shares, and a sale of 21,801 common shares at $13.10 per share. After the transactions, reported beneficial ownership totals shown range between 134,357 and 160,507 shares depending on which line is referenced; derivative holdings converted on a one-for-one basis into common stock.

Positive

  • Converted PRSUs to common stock totaling 17,752 and 26,150 units, increasing equity alignment with shareholders
  • Participated in ESPP with a purchase of 254 shares, indicating continued employee ownership
  • Disclosures reference grant dates and one-for-one conversion, improving transparency

Negative

  • Sold 21,801 shares at $13.10, representing insider liquidity that partially reduces holdings
  • Beneficial ownership figures vary by line (134,357 to 160,507), which may require careful reconciliation by investors

Insights

TL;DR: Insider activity shows mixed transactions: PRSU conversions and an ESPP buy alongside a notable open-market sale.

The filing documents non-cash PRSU conversions totaling 43,902 units (17,752 + 26,150) that convert one-for-one into common shares, increasing share exposure without cash outlay. The ESPP purchase of 254 shares is routine employee participation. The sale of 21,801 shares at $13.10 partially offsets those increases and represents realized insider liquidity. Overall, the activity is typical compensation-related vesting plus a voluntary sale and does not by itself indicate a material change to company fundamentals.

TL;DR: Transactions appear consistent with executive compensation vesting and routine insider selling; disclosures are timely and complete.

The report identifies PRSU grants from prior years (grants dated Aug 24, 2023 and Aug 26, 2024) that vested or converted on 08/31/2025 and are disclosed as required. The presence of an ESPP purchase and a contemporaneous open-market sale suggests portfolio rebalancing or personal liquidity rather than governance concerns. The Form 4 is signed via power of attorney and includes explanatory footnotes about grant dates and one-for-one conversion, aligning with standard disclosure practice.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cunningham Kristen

(Last) (First) (Middle)
3300 TRIUMPH BLVD, SUITE 700

(Street)
LEHI UT 84043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Lifevantage Corp [ LFVN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Sales Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/31/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/31/2025 M 17,752(1) A $0 134,357(2) D
Common Stock 08/31/2025 M 26,150(3) A $0 160,507 D
Common Stock 08/31/2025 F 21,801 D $13.1 138,706 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Performance Restricted Stock Units (4) 08/31/2025 M 17,752 (1) (1) Common Stock 17,752 $0 5,917 D
Performance Restricted Stock Units (4) 08/31/2025 M 26,150 (3) (3) Common Stock 26,150 $0 13,075 D
Explanation of Responses:
1. On August 24, 2023, the reporting person was granted Performance Restricted Stock Units ("PRSUs") which vest upon achievement of previously established time-based and financial performance criteria.
2. Includes 254 total shares purchased on August 31, 2025 under the Employee Stock Purchase Plan.
3. On August 26, 2024, the reporting person was granted PRSUs which vest upon achievement of previously established time-based and financial performance criteria.
4. PRSUs convert into common stock on a one-for-one basis.
Remarks:
/s/ Alissa Neufeld, Power of Attorney for Kristen Cunningham 09/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Kristen Cunningham report on Form 4 for LFVN?

The filing reports conversion/acquisition of 17,752 and 26,150 PRSUs into common stock, an ESPP purchase of 254 shares, and a sale of 21,801 shares at $13.10 per share, all dated 08/31/2025.

How do PRSUs reported by Kristen Cunningham convert into LFVN common stock?

The filing states PRSUs convert one-for-one into common stock upon vesting, as noted in the explanatory remarks.

Did the Form 4 indicate when the PRSUs were originally granted?

Yes. The filing notes PRSU grants on 08/24/2023 and 08/26/2024 tied to time-based and financial performance criteria.

What is the effect on Kristen Cunningham’s ownership after the reported transactions?

Post-transaction beneficial ownership amounts reported on the form include figures such as 134,357, 138,706, and 160,507 shares depending on the line item; the form should be consulted for precise reconciliation.

Who signed the Form 4 filing for Kristen Cunningham?

The Form 4 was signed by Alissa Neufeld, Power of Attorney for Kristen Cunningham on 09/03/2025.
Lifevantage Corp

NASDAQ:LFVN

LFVN Rankings

LFVN Latest News

LFVN Latest SEC Filings

LFVN Stock Data

80.40M
10.48M
16.79%
65.65%
19.95%
Packaged Foods
Pharmaceutical Preparations
Link
United States
LEHI